Aura Biosciences annual free cash flow
2020
2021
2022
2023
2024
2025
Aura Biosciences Free Cash Flow (FCF) History (AURA)
Aura Biosciences reported −$85.2M in free cash flow for fiscal 2025, a decrease of $4.1M from the previous fiscal year.
View full Aura Biosciences company overviewAura Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$85.2M | −$4.1M | — | — |
| 2024 | 2024-12-31 | −$81.1M | −$16.5M | — | — |
| 2023 | 2023-12-31 | −$64.6M | −$8.9M | — | — |
| 2022 | 2022-12-31 | −$55.7M | −$21.2M | — | — |
| 2021 | 2021-12-31 | −$34.5M | −$9.4M | — | — |
| 2020 | 2020-12-31 | −$25.1M | — | — | — |
Aura Biosciences quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$32.5M | −$11.7M | — | — |
| Q1 2026 | 2026-03-31 | −$30.0M | −$6.5M | — | — |
| Q4 2025 | 2025-12-31 | −$20.6M | $3.6M | — | — |
| Q3 2025 | 2025-09-30 | −$20.2M | −$4.6M | — | — |
| Q2 2025 | 2025-06-30 | −$20.8M | −$4.2M | — | — |
| Q1 2025 | 2025-03-31 | −$23.5M | $998,000 | — | — |
| Q4 2024 | 2024-12-31 | −$24.3M | −$6.5M | — | — |
| Q3 2024 | 2024-09-30 | −$15.6M | −$121,000 | — | — |
| Q2 2024 | 2024-06-30 | −$16.7M | −$1.8M | — | — |
| Q1 2024 | 2024-03-31 | −$24.5M | −$8.0M | — | — |
| Q4 2023 | 2023-12-31 | −$17.7M | $667,000 | — | — |
| Q3 2023 | 2023-09-30 | −$15.5M | −$4.7M | — | — |
| Q2 2023 | 2023-06-30 | −$14.8M | −$4.1M | — | — |
| Q1 2023 | 2023-03-31 | −$16.5M | −$722,000 | — | — |
| Q4 2022 | 2022-12-31 | −$18.4M | −$5.5M | — | — |
| Q3 2022 | 2022-09-30 | −$10.8M | −$1.6M | — | — |
| Q2 2022 | 2022-06-30 | −$10.7M | −$3.5M | — | — |
| Q1 2022 | 2022-03-31 | −$15.8M | −$10.6M | — | — |
| Q4 2021 | 2021-12-31 | −$12.9M | — | — | — |
| Q3 2021 | 2021-09-30 | −$9.3M | — | — | — |
| Q2 2021 | 2021-06-30 | −$7.2M | — | — | — |
| Q1 2021 | 2021-03-31 | −$5.2M | — | — | — |
Aura Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$25.1M to −$85.2M, a net decrease of $60.1M. Aura Biosciences's latest reported quarter, Q2 2026, generated −$32.5M in free cash flow, a decrease of $11.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Aura Biosciences filings at SEC.gov ↗